Kintara Therapeutics, Inc. (KTRA)
Market Cap | 14.33M |
Revenue (ttm) | n/a |
Net Income (ttm) | -9.51M |
Shares Out | 55.30M |
EPS (ttm) | -4.07 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,593,443 |
Open | 0.285 |
Previous Close | 0.298 |
Day's Range | 0.255 - 0.295 |
52-Week Range | 0.081 - 5.600 |
Beta | 0.70 |
Analysts | Strong Buy |
Price Target | 14.00 (+5,303.32%) |
Earnings Date | May 14, 2024 |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous m... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for KTRA stock is "Strong Buy" and the 12-month stock price forecast is $14.0.
News
![](https://cdn.snapi.dev/images/v1/a/m/press16-2504626.jpg)
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
SAN DIEGO , July 1, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, and TuHURA B...
![](https://cdn.snapi.dev/images/v1/6/l/press17-2458919.jpg)
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks Eighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or a...
![](https://cdn.snapi.dev/images/v1/a/m/press20-2430852.jpg)
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
SAN DIEGO , May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
![](https://cdn.snapi.dev/images/v1/r/q/press1-2364416.jpg)
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti...
![](https://cdn.snapi.dev/images/v1/q/i/press1-2359127.jpg)
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Therap...
![](https://cdn.snapi.dev/images/v1/b/p/press19-2355030.jpg)
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating Kintara (Nasdaq: KTRA) for possible breaches of fiduciary duty and other violations of law in its transaction with TuHURA. Click he...
![](https://cdn.snapi.dev/images/v1/y/3/press11-2354353.jpg)
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kinta...
![](https://cdn.snapi.dev/images/v1/d/d/press18-2353832.jpg)
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 un...
![](https://cdn.snapi.dev/images/v1/7/i/press10-2343918.jpg)
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
![](https://cdn.snapi.dev/images/v1/h/c/press14-2276757.jpg)
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
![](https://cdn.snapi.dev/images/v1/n/u/press12-2271461.jpg)
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
- 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Phase 3 Clinical Trial in CMBC Patients - SAN DIEGO , Feb. 12, 2024 /PRNewswire/ -- Kintara Therapeutics, ...
![](https://cdn.snapi.dev/images/v1/x/i/image13-2213089.jpg)
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/x/x/image22-2199829.jpeg)
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/m/y/press8-2187501.jpg)
Kintara Therapeutics Announces Review of Strategic Alternatives
- Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO , Dec. 7, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused o...
![](https://cdn.snapi.dev/images/v1/h/4/press14-2183771.jpg)
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
SAN DIEGO , Dec. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
![](https://cdn.snapi.dev/images/v1/i/t/insurance7-2179943.jpg)
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/s/j/press15-2155589.jpg)
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
![](https://cdn.snapi.dev/images/v1/g/5/press12-2130111.jpg)
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
- VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities - SAN DIEGO , Oct. 31...
![](https://cdn.snapi.dev/images/v1/8/9/conf19-2098516.jpg)
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
![](https://cdn.snapi.dev/images/v1/f/j/conf5-2085601.jpg)
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
SAN DIEGO , Oct. 2, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
![](https://cdn.snapi.dev/images/v1/g/4/press1-2076006.jpg)
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
SAN DIEGO , Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, ...
![](https://cdn.snapi.dev/images/v1/e/a/press5-2068200.jpg)
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
SAN DIEGO , Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
![](https://cdn.snapi.dev/images/v1/9/9/conf9-2049118.jpg)
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
![](https://cdn.snapi.dev/images/v1/q/s/press20-2028037.jpg)
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
SAN DIEGO , Aug. 17, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
![](https://cdn.snapi.dev/images/v1/y/m/conf19-2014565.jpg)
Kintara Therapeutics to Present at the Emerging Growth Conference
SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...